Tonix Q4 Revenue Up 109% to $5.39M, TONMYA Records 4,200 Prescriptions
Tonix Pharmaceuticals posted Q4 revenue of $5.39M, a 109% increase year-over-year and $2.42M above consensus, but GAAP EPS of -$3.98 fell short of estimates. TONMYA’s launch yielded 4,200 prescriptions from 1,500 prescribers despite insurance hurdles; $138.8M operating expenses drove $124M net loss and $207.6M cash supports operations into Q1 2027.
1. Q4 Financial Results
Tonix delivered Q4 revenue of $5.39M, marking a 109% year-over-year increase and $2.42M above analyst consensus. GAAP EPS was -$3.98, missing estimates due to elevated R&D and SG&A expenditures.
2. TONMYA Commercial Launch
The first quarter of TONMYA commercialization generated 4,200 prescriptions from more than 1,500 prescribers, signaling early market traction. Insurance coverage limitations remain a key barrier to revenue conversion.
3. Financial Position and Runway
Operating expenses totaled $138.8M for FY25, resulting in a $124M net loss. With $207.6M in cash on hand, Tonix projects funding its operations through at least Q1 2027.
4. AACR Presentation Highlights
Tonix will present an oral session on TFF2 deficiency’s role in gastric tumor progression and two posters on anti-BTLA antibodies and TNX-1700 pharmacokinetics at the AACR Annual Meeting April 17–22, showcasing its preclinical immuno-oncology pipeline.